WORLD JOURNAL OF SURGICAL ONCOLOGY

Soft tissue sarcomas (STSs) are members of a heteroge-neous group of tumors that encompasses more than 50 subtypes. The majority of STSs are located in the limbs. The mainstay of local treatment for sarcomas of the ex-tremities is limb-sparing surgery with complete tumor resection and clear surgical margins [1]. Hyperthermic isolated limb perfusion with tumor ne-crosis factor-α (TNF-α) and melphalan (TM-HILP) is a promising local treatment for locally advanced STSs, such as nonresectable STSs of the limbs, and has resulted in high tumor response rates and high limb sal-vage rates [2]. STSs represent a heterogeneous group of malignancies with different tumor biology and prognoses; however, the pathological grading, clinical evaluation and treat-ment of STS types follow common principles. Published data on the effectiveness and outcomes of TM-HIL